| | Identification | Back Directory |  | [Name] 
 LEVOCABASTINE HYDROCHLORIDE
 |  | [CAS] 
 79547-78-7
 |  | [Synonyms] 
 547
 R50547
 LIVOSTIN
 LEVOPHTA
 LEVOSTIN
 Unii-124xma6yei
 (3S,4R)-Cabastine
 LEVOCABASTINE HCL
 LIVOSTIN USP/EP/BP
 (3S,4R)-Cabastine HCl
 LEVOCABASTINE HYDROCHLORIDE
 (3S,4R)-Cabastine Hydrochloride
 Levocabastine hydrochloride CRS
 Levocabastine Hydrochloride (50 mg)
 Levocabastine Hydrochloride (1359856)
 Levocabastine for system suitability 2
 Levocabastine for system suitability 1 CRS
 Levocabastine for system suitability 2 CRS
 1-(4-Cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-4-phenylpiperidine-4-carboxylic acid monohydrochloride
 [3s-[1(cis),3α,4β]]-1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenyl-4-piperidinecarboxylic acid
 (3S,4R)-1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenylpiperidine-4-carboxylicacid,hydrochloride
 1-(4-Cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-4-phenylpiperidine-4-carboxylic acid monohydrochloride USP/EP/BP
 (3S,4R)-1-[cis-4-Cyano-4-(4-fluorophenyl)cyclohexyl]- 3-methyl-4-phenylpiperidine-4-carboxylic acid monohydrochloride
 4-Piperidinecarboxylicacid, 1-[cis-4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenyl-,hydrochloride (1:1), (3S,4R)-
 4-Piperidinecarboxylic acid, 1-(cis-4-cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-4-phenyl-, monohydrochloride, (3S,4R)-
 [3S-[1(CIS),3ALPHA,4BETA]]-1-[4-CYANO-4-(4-FLUOROPHENYL)CYCLOHEXYL]-3-METHYL-4-PHENYL-4-PIPERIDINECARBOXYLIC ACID HYDROCHLORIDE
 4-Piperidinecarboxylic acid, 1-[cis-4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenyl-, monohydrochloride, (3S,4R)- (9CI)
 4-Piperidinecarboxylic acid, 1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenyl-, monohydrochloride, [3S-[1(cis),3a,4b]]-
 Levophta,  Levostin,  R50547,  [3S-[1(cis),3α,4β]]-1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenyl-4-piperidinecarboxylic  acid
 |  | [EINECS(EC#)] 
 209-062-5
 |  | [Molecular Formula] 
 C26H30ClFN2O2
 |  | [MDL Number] 
 MFCD07787408
 |  | [MOL File] 
 79547-78-7.mol
 |  | [Molecular Weight] 
 456.98
 | 
 | Hazard Information | Back Directory |  | [Chemical Properties] 
 White or almost white powder.
 |  | [Uses] 
 A histamine H1 receptor antagonist
 |  | [Brand name] 
 Livostin (Novartis).
 |  | [Description] 
 Levocabastine hydrochloride is a new, highly potent and specific histamine HI-receptor
antagonist without anticholinergic or antiserotonergic side effects. It is reported to
have both a fast onset and long duration of action. Indications are the treatment of
allergic conjunctivitis and allergic rhinitis.
 |  | [Originator] 
 Janssen (Johnson & Johnson) (U.S.A.)
 |  | [Definition] 
 ChEBI: Livostin (TN) is a member of piperidines.
 |  | [Manufacturing Process] 
 4-Cyano-4-(4-fluorophenyl)-heptanedioic acid diethyl ester is obtained by
addition of ethyl acrylate to the anion from p-fluorophenylacetonitrile. By base
catalyzed cyclization of these diester (sodium methoxide, 60°C, xylene) is
synthesized an intermediate that after decarboethoxylation gives 1-(4-
fluorophenyl)-4-oxycyclohexanecarbonitrile. By condensation of 3-methyl-5-
phenylpiperidine-4-carboxylic acid benzyl ester and 1-(4-fluorophenyl)-4-
oxycyclohexanecarbonitrile under reductive hydrogenation conditions
(palladium-on-charcoal catalyst, 50°C, in ethanol) is prepared benzyl ester 4-
piperidinecarboxylic acid, 1-(4-cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-
4-phenyl-, (3S-(1(cis),3α,4β))-. The benzyl protecting group is then removed
by hydrogenation method and 4-piperidinecarboxylic acid, 1-(4-cyano-4-(4-
fluorophenyl)cyclohexyl)-3-methyl-4-phenyl-, (3S-(1(cis),3α,4β))- obtained is
transformed into 4-piperidinecarboxylic acid, 1-(4-cyano-4-(4-fluorophenyl)
cyclohexyl)-3-methyl-4-phenyl-, hydrochloride, (3S-(1(cis), 3α,4β))-
(Levocabastine hydrochloride)
 |  | [Therapeutic Function] 
 Antihistaminic
 | 
 | 
                    
                        
                            | Company Name: | LGM Pharma |  
                            | Tel: | 1-(800)-881-8210 |  
                            | Website: | www.lgmpharma.com |  |